https://scholars.lib.ntu.edu.tw/handle/123456789/543231
標題: | Development of nanosome-encapsulated honokiol for intravenous therapy against experimental autoimmune encephalomyelitis | 作者: | Hsiao, Y.-P. Chen, H.-T. Liang, Y.-C. Wang, T.-E. Huang, K.-H. Hsu, C.-C. Liang, H.-J. Huang, C.-H. CHENG-CHIH HSU TONG-RONG JAN |
公開日期: | 2020 | 卷: | 15 | 起(迄)頁: | 17-29 | 來源出版物: | International Journal of Nanomedicine | 摘要: | Background: Honokiol has been reported to possess anti-inflammatory and neuroprotective activities. However, the poor aqueous solubility of honokiol limits its clinical application for systemic administration. Purpose: This study aims to develop a novel formulation of nanosome-encapsulated honokiol (NHNK) for intravenous therapy against mouse experimental autoimmune encephalomyelitis (EAE) that mimics human multiple sclerosis. Methods: Nanosomes and NHNK were prepared by using an ultra-high pressure homogenization (UHPH) method. Mice were treated with NHNK or empty nanosomes during the peak phase of EAE symptoms. Symptoms of EAE were monitored and samples of the spinal cord were obtained for histopathological examinations. Results: The stock of NHNK containing honokiol in the nanosome formulation, which showed the structure of single phospholipid bilayer membranes, was well formulated with the particle size of 48.0 ± 0.1 nm and the encapsulation efficiency 58.1 ± 4.2%. Intravenous administration of NHNK ameliorated the severity of EAE accompanied by a significant reduction of demyelination and inflammation in the spinal cord. Furthermore, NHNK decreased the number of IL-6+, Iba-1+TNF+, Iba-1+IL-12 p40+, and CD3+IFN-γ+ cells infiltrating the spinal cord. Conclusion: The UHPH method simplified the preparation of NHNK with uniformly distributed nanosize and high encapsulation efficiency. Intravenous administration of NHNK ameliorated the severity of EAE by suppressing the infiltration of activated microglia and Th1 cells into the spinal cord. Collectively, these results suggest that the formulation of NHNK is a prospective therapeutic approach for inflammatory CNS diseases, such as multiple sclerosis. ? 2020 Hsiao et al. |
URI: | https://www.scopus.com/inward/record.url?eid=2-s2.0-85078260417&partnerID=40&md5=e0a8fe3f86de07289498adac7e380369 https://scholars.lib.ntu.edu.tw/handle/123456789/543231 |
DOI: | 10.2147/IJN.S214349 | SDG/關鍵字: | honokiol; nanoparticle; nanosome; unclassified drug; antiinflammatory agent; biphenyl derivative; honokiol; lignan; nanomaterial; neuroprotective agent; animal experiment; animal model; Article; controlled study; drug formulation; experimental autoimmune encephalomyelitis; female; mouse; multiple sclerosis; nanoencapsulation; nonhuman; animal; C57BL mouse; chemistry; drug delivery system; drug effect; experimental autoimmune encephalomyelitis; intravenous drug administration; microglia; multiple sclerosis; myelitis; pathology; procedures; spinal cord; Th1 cell; Animals; Anti-Inflammatory Agents; Biphenyl Compounds; Drug Delivery Systems; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intravenous; Lignans; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Myelitis; Nanostructures; Neuroprotective Agents; Spinal Cord; Th1 Cells |
顯示於: | 化學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。